- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07572526
tDCS: Sleep to Mood in Depression (S2M-D)
Sleep Consolidation as a Mechanistic Pathway Linking Home-Based tDCS to Antidepressant Response (S2M-D)
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This study evaluates the effects of home-based transcranial direct current stimulation (tDCS) on sleep and depressive symptoms in adults with moderate depression. tDCS is a noninvasive neuromodulation technique that delivers a mild electrical current to the scalp to modulate brain activity and has been studied as a potential treatment for depression.
Participants will self-administer tDCS for 20 sessions at home over the course of the study. Sleep will be continuously monitored using a wearable device called an Oura Ring that captures sleep measures such as sleep duration, efficiency, awakenings, and night-to-night consistency. Depressive symptoms will be assessed longitudinally using validated clinical and self-report measures.
The primary objective is to determine whether changes in sleep consolidation occur over the course of tDCS treatment. A secondary objective is to evaluate whether changes in sleep are temporally associated with improvements in depressive symptoms.
This study aims to better characterize the relationship between sleep and depressive response during tDCS, and to identify potential sleep-related markers associated with clinical improvement in depression.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Shayna Pehel
- Telefoonnummer: 929-455-5104
- E-mail: Shayna.Pehel@nyulangone.org
Studie Contact Back-up
- Naam: Giuseppina Pilloni
- Telefoonnummer: 929-455-5317
- E-mail: Giuseppina.Pilloni@nyulangone.org
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10016
- Werving
- NYU Langone Health
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Ability to read and understand study materials in English, as demonstrated by a standard score >85 on the WRAT-5 Reading Recognition Subtest
- MADRS-S ≥18 during screening
- Confirmed diagnosis of MDD, based on clinician interview
- If taking antidepressant medication, the dose must be stable for at least 30 days prior to pre-screening.
- Confirmed access to a local provider that has primary responsibility for the subjects' clinical care, and who is available for contact in case of increased subject risk due to depressive symptoms OR confirmed acknowledgement and identification of local resources.
- Able to provide informed consent and comply with study procedures.
- Access to a quiet space suitable for home-based tDCS stimulation sessions.
Exclusion Criteria:
- Current major medical condition that, in the opinion of the study clinician, would interfere with study participation, safety, or interpretation of study outcomes.
- Current or past bipolar disorder, psychotic disorder, or current (past 6 months) alcohol or substance use disorder, as determined by clinician assessment at screening.
- Clinically significant suicidal ideation or behavior, based on clinician assessment and the Columbia-Suicide Severity Rating Scale (C-SSRS).
- Use of prescription or over-the-counter sleep-promoting medications or initiation of behavioral interventions specifically targeting sleep in the past 30 days from pre-screening.
- History of seizure disorder or epilepsy.
- Presence of an active implanted medical device above the neck (e.g., deep brain stimulator, cochlear implant) or non-MRI-compatible metallic implants in the head or neck region.
- Current use of prescription or over-the-counter sleep medications, or active participation in any behavioral or pharmacologic treatment specifically targeting sleep.
- Pregnancy and Breastfeeding: Currently pregnant, planning pregnancy during the study period, or breastfeeding o If able to become pregnant, participants will be required to use medically accepted birth control methods, including hormonal methods (e.g., pills, patches, implants), barrier methods (e.g., condoms or diaphragm with spermicide), intrauterine device (IUD), or abstinence. Participants will be advised not to become pregnant during the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Active transcranial direct current stimulation (tDCS)
Participants will complete a 20-session course of home-based left dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) (2.0 mA, 30 minutes per session).
|
Transcranial direct current stimulation delivers a gentle, low-intensity electrical current.
The tDCS device is programmed to ramp up to 2.0 mA (for 30 seconds), deliver constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end of the session.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in sleep efficiency
Tijdsspanne: Baseline, Post-Intervention (Week 5)
|
Sleep efficiency (SE) is the percentage of time spent asleep while in bed.
A healthy, normal efficiency is 85% or higher, with 90% or more considered very good.
Low efficiency can indicate poor sleep quality.
|
Baseline, Post-Intervention (Week 5)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in wake after sleep onset (WASO)
Tijdsspanne: Baseline, Post-Intervention (Week 5)
|
WASO represents the sum of all wakefulness durations after sleep initiation.
|
Baseline, Post-Intervention (Week 5)
|
|
Change in night-to-night variability in sleep efficiency
Tijdsspanne: Baseline, Post-Intervention (Week 5)
|
Night-to-night variability in sleep efficiency is measured as the percentage of time in bed actually spent sleeping.
High variability can indicate poor sleep quality.
|
Baseline, Post-Intervention (Week 5)
|
|
Change in total sleep time
Tijdsspanne: Baseline, Post-Intervention (Week 5)
|
Baseline, Post-Intervention (Week 5)
|
|
|
Change in sleep latency
Tijdsspanne: Baseline, Post-Intervention (Week 5)
|
Sleep latency is the time it takes to transition from full wakefulness to sleep.
An ideal sleep latency is typically 10-20 minutes.
|
Baseline, Post-Intervention (Week 5)
|
|
Change in Montgomery-Åsberg Depression Rating Scale (MADRS-S) score
Tijdsspanne: Baseline, Final Follow-Up Study Visit (Month 2)
|
MADRS-s is a 10-item self report questionnaire used to measure the severity of depressive episodes in patients with mood disorders.
Each item is rated on a 0-6 scale, resulting in a total score range of 0-60.
The higher the score, the more severe the depression.
|
Baseline, Final Follow-Up Study Visit (Month 2)
|
|
Change in Patient Health Questionnaire-8 (PHQ-8) score
Tijdsspanne: Baseline, Final Follow-Up Study Visit (Month 2)
|
The PHQ-8 consist of 8-items.
Participants self-report the severity of current depression.
Each item is scored 0-3 based on frequency (0: Not at all, 1: Several days, 2: More than half the days, 3: Nearly every day), with a total score ranging from 0 to 24.
Higher scores indicate severe depression.
|
Baseline, Final Follow-Up Study Visit (Month 2)
|
|
Change in Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) score
Tijdsspanne: Baseline, Final Follow-Up Study Visit (Month 2)
|
The QIDS-SR is a 16-item self-report tool used to measure the severity of depressive symptoms.
Scores range from 0-27, with higher scores indicating clinically significant depression.
|
Baseline, Final Follow-Up Study Visit (Month 2)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Giuseppina Pilloni, NYU Langone Health
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Psychische aandoening
- Gedragssymptomen
- Stemmingsstoornissen
- Depressieve stoornis
- Gedrag
- Depressie
- Depressieve stoornis, majoor
- Therapeutica
- Gedragsdisciplines en activiteiten
- Elektrische stimulatietherapie
- Convulsieve therapie
- Psychiatrische somatische therapieën
- Electroshock
- Psychologische technieken
- Transcraniale directe stroomstimulatie
Andere studie-ID-nummers
- 26-00329
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .